Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_7da60b0_112841_Lewis_Eldrin_BOSTON.jpg)
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
Key clinical point:Patients with type 2 diabetes who are treated with lixisenatide or sitagliptin are at no greater risk for heart failure than if...